Bertoluci, Marcello Casaccia
Silva Júnior, Wellington S.
Valente, Fernando
Araujo, Levimar Rocha
Lyra, Ruy
de Castro, João Jácome
Raposo, João Filipe
Miranda, Paulo Augusto Carvalho
Boguszewski, Cesar Luiz
Hohl, Alexandre
Duarte, Rui
Salles, João Eduardo Nunes
Silva-Nunes, José
Dores, Jorge
Melo, Miguel
de Sá, João Roberto
Neves, João Sérgio
Moreira, Rodrigo Oliveira
Malachias, Marcus Vinícius Bolívar
Lamounier, Rodrigo Nunes
Malerbi, Domingos Augusto
Calliari, Luis Eduardo
Cardoso, Luis Miguel
Carvalho, Maria Raquel
Ferreira, Hélder José
Nortadas, Rita
Trujilho, Fábio Rogério
Leitão, Cristiane Bauermann
Simões, José Augusto Rodrigues
dos Reis, Mónica Isabel Natal
Melo, Pedro
Marcelino, Mafalda
Carvalho, Davide
Article History
Received: 21 May 2023
Accepted: 23 June 2023
First Online: 19 July 2023
Declarations
:
: Not applicable.
: All authors approved for publication.
: CL: No competing interests; CLB: No competing interests; DACM: No competing interests; DC: AstraZeneca, Bial, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi-Aventis, Servier; FRT: Abbott, Aché, AstraZeneca, Boehringer Ingelheim, Eli Lilly do Brasil, Eurofarma, HAUX, Mantecorp, Merck, Novo Nordisk, Sanofi, Servier, Takeda; FV: Novo Nordisk, AstraZeneca, Boehringer-Lilly, Abbott; HJF: No competing interests; JARS: No competing interests; JD: Novo Nordisk, Lilly, LifeScan, Amgen, Abbott, AstraZeneca, Boehringer Ingelheim, Ascencia Diabetes Care, MSD; JENS: Abbott Nutrition, AstraZeneca, Bayer Boeringher-Ingelheim, Eli Lilly, Merck Serono, Novartis, Novo Nordisk, Servier, Takeda; JFR: No competing interests; JJC: Abbott Diagnostics, AstraZeneca, BIAL, Boehringer-Ingelheim, Lilly, Menarini Diagnostics, Menarini Pharma, Merck Serono, MSD, Novartis, Novo Nordisk, Recordatti, Sanofi, Takeda; JRS: No competing interests; JSN: Abbott, AstraZeneca, Bial, Boehringer Ingelheim, Eli Lilly & Company, Janssen Pharmaceuticals, Medinfar, Merck SA, MSD, Mundipharma, Novartis Pharmaceuticals, Novo Nordisk, Roche, Sanofi, Servier, Tecnimede; JSN: AstraZeneca, BIAL, Boehringer Ingelheim, Lilly, Medinfar, Merck, MSD, Novartis, Novo Nordisk, Sanofi; LC: No competing interests; LEC: Abbott, Medtronic, Novo Nordisk, Roche; LRA: No competing interests; MCB: AstraZeneca, Aché, Boehringer-Ingelheim, Bayer, Novo Nordisk, Lilly; MINR: No competing interests; MM: Abbott, AstraZeneca, Bayer, Bial, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, Sanofi/Genzyme; MM: No competing interests; MRC: No competing interests; MVBM: Abbott, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Libbs, Lilly, Novartis, Novo Nordisk, Roche, Viatris; PACM: No competing interests; PM: AstraZeneca, Novo Nordisk; RD: No competing interests; RLSF: Aché, Boheringer, Lilly, Mantecorp, Bracepharma, Novo Nordisk, Merck Serono, Procter & Gamble; AH Novo Nordisk; RN: No competing interests; RNL: No competing interests; ROM: AstraZeneca, Novo Nordisk, Servier, Merck, Eurofarma, Bayer; WSSJ: Abbott, AstraZeneca, Libbs, Mantecorp, Merck, Novo Nordisk, Servier, Torrent.